Literature DB >> 1856156

Effect of anticoagulants in vitro on the viability of lymphocytes and content of free fatty acids in plasma.

A Klein1, S Ramcharitar, N Christeff, E Nisbett-Brown, E Nunez, A Malkin.   

Abstract

These authors attempted to test the effect of anticoagulants on lymphocytes viability by reproducing the procedure used for lymphocyte isolation for various immunologic tests in which blood specimens are allowed to stay at room temperature for 2 h before lymphocytes are isolated. Blood was obtained with three different anticoagulants i.e. heparin, citrate, and CPDA (citrate, phosphate, dextrose, and adenine). Plasma was lyophilized and extracted with ethanol. Dried ethanol extracts were suspended in medium (RPMI 1640 + 10% fetal bovine serum) and incubated with a lymphocyte cell line (MOLT-4). After 24 h of incubation the viability of cells was examined. The following death rates of the cells were observed: heparin -63 +/- 4.6% (mean +/- SEM), citrate -27 +/- 6.7%, and CPDA 6.2 +/- 0.6% (P less than 0.0005). A significant correlation was found between these results and changes in the concentrations of free fatty acids in the extracts. These results emphasize the importance of choosing the right anticoagulant when the viability of lymphocytes is obligatory.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1856156     DOI: 10.1007/bf02630908

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  16 in total

1.  Sera of patients with cancer or cirrhosis and of newborns exhibiting inhibitory effects on the metabolism of cortisol by lymphocytes.

Authors:  A Klein; S M Archer; A Malkin
Journal:  J Natl Cancer Inst       Date:  1986-07       Impact factor: 13.506

Review 2.  Fatty acids and immunity.

Authors:  C J Meade; J Mertin
Journal:  Adv Lipid Res       Date:  1978

3.  Activation of lipoprotein lipase. Comparative study of man and other mammals.

Authors:  T F Whayne; J M Felts
Journal:  Circ Res       Date:  1970-05       Impact factor: 17.367

4.  Cytotoxic activity of unsaturated fatty acids to lymphocytes.

Authors:  K Kageyama; T Nagasawa; S Kimura; T Kobayashi; Y Kinoshita
Journal:  Can J Biochem       Date:  1980-06

5.  Effect of ethanol extract of cancer patients' serum on the vulnerability of lymphocytes to cortisol.

Authors:  A Klein; B Bruser; A Malkin
Journal:  Tumour Biol       Date:  1988

6.  cis-Unsaturated fatty acids uncouple mitochondria and stimulate glycolysis in intact lymphocytes.

Authors:  P Arslan; A N Corps; T R Hesketh; J C Metcalfe; T Pozzan
Journal:  Biochem J       Date:  1984-01-15       Impact factor: 3.857

7.  Pharmacological activities of heparins obtained from different tissues: enrichment of heparin fractions with high lipoprotein lipase, antihemolytic and anticoagulant activities by molecular sieving and antithrombin III affinity chromatography.

Authors:  P Bianchini; B Osima; B Parma; H B Nader; C P Dietrich
Journal:  J Pharmacol Exp Ther       Date:  1982-02       Impact factor: 4.030

8.  Hemodialysis and cell toxicity in vitro related to plasma triglycerides, post-heparin lipolytic activity and free fatty acids.

Authors:  T Wessel-Aas; J P Blomhoff; E Wirum; T Nilsen
Journal:  Acta Med Scand       Date:  1984

9.  Effect of a non-viral fraction of acquired immunodeficiency syndrome plasma on the vulnerability of lymphocytes to cortisol.

Authors:  A Klein; B Bruser; J B Robinson; P H Pinkerton; A Malkin
Journal:  J Endocrinol       Date:  1987-02       Impact factor: 4.286

10.  Effects of free fatty acids on the organization of cytoskeletal elements in lymphocytes.

Authors:  R L Hoover; K Fujiwara; R D Klausner; D K Bhalla; R Tucker; M J Karnovsky
Journal:  Mol Cell Biol       Date:  1981-10       Impact factor: 4.272

View more
  1 in total

1.  Novel Cell Preservation Technique to Extend Bovine In Vitro White Blood Cell Viability.

Authors:  Emilie L Laurin; Shawn L B McKenna; Javier Sanchez; Horacio Bach; Juan Carlos Rodriguez-Lecompte; Marcelo Chaffer; Greg P Keefe
Journal:  PLoS One       Date:  2015-10-08       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.